Research Associate - A Versatile Biocatalytic Platform for Scalable Therapeutic Oligonucleotide[...]

TN United Kingdom; Manchester; On-site; GBP 40,000 - 80,000; Full time

Job summary

An established industry player is seeking a Postdoctoral Research Associate to contribute to groundbreaking research in therapeutic oligonucleotide manufacturing. This role involves developing a versatile biocatalytic platform, addressing scalability challenges in current synthesis methods. You will work at the Manchester Institute of Biotechnology, collaborating with leading companies in the pharmaceutical sector. If you have a strong background in directed evolution and biochemistry, this is an exciting opportunity to make a significant impact in drug development.

Qualifications

• Experience in directed evolution and biocatalysis is essential.
• Strong background in biochemistry or related disciplines.

Responsibilities

• Develop and optimize biocatalytic methods for oligonucleotide synthesis.
• Collaborate with industry partners on innovative projects.

Skills

Directed Evolution

Biocatalysis

Biochemistry

Education

PhD in Biochemistry or related field

Job description

Research Associate - A Versatile Biocatalytic Platform for Scalable Therapeutic Oligonucleotide Manufacturing, Manchester

Client:

The University of Manchester

Location:

Manchester, United Kingdom

Job Category:

Other

EU work permit required:

Yes

Job Reference:

730dc0004e76

Job Views:

6

Posted:

02.05.2025

Expiry Date:

16.06.2025

Job Description:

Research Focus: Development of a versatile biocatalytic platform for scalable therapeutic oligonucleotide manufacturing.

Position: Postdoctoral Research Associate with experience in directed evolution, biocatalysis, biochemistry, or related disciplines.

Objective: To develop and optimize biocatalytic methods for therapeutic oligonucleotide synthesis.

Location: Manchester Institute of Biotechnology (MIB), supervised by Dr. Sarah Lovelock, with collaboration with industry partners such as AstraZeneca, Novartis, CPI, Novo Nordisk, and BioMarin.

Background: Therapeutic oligonucleotides target mRNA to modulate protein production and represent a promising drug modality. Current chemical synthesis methods face scalability limitations.